Case Studies
Gallium in CF Lung Infection: Targeting Bacterial Iron
Clinical Overview
This translational study evaluates intravenous gallium nitrate, a Ga³⁺ iron mimetic, as an antimicrobial strategy for chronic Pseudomonas aeruginosa lung infection in adults with cystic fibrosis (CF). CF sputum was shown to be iron limited, and low micromolar gallium (≥4–5 μM) inhibited P. aeruginosa growth ex vivo in CF sputum. In a 5-day continuous-infusion phase 1b trial (n=20, age 19–54 years), gallium nitrate 100 or 200 mg/m²/day improved lung function: mean FEV₁ increased by 0.13 L at day 14 and 0.10 L at day 28 (both p≈0.004) without significant nephrotoxicity. Mouse lung-infection models and mechanistic assays support that Ga³⁺ disrupts bacterial Fe-dependent metabolism and enhances oxidant susceptibility.
Study Setting
Work was conducted in a clinical CF population and complementary laboratory models. Adults with CF and chronic P. aeruginosa infection from three US centers were enrolled, excluding those with FEV₁ <30% predicted or significant renal/hepatic disease; participants were clinically stable, not in acute exacerbation. Gallium nitrate, an FDA-approved intravenous Ga³⁺ formulation, was infused over 5 days (100 or 200 mg/m²/day), providing systemic exposure and sputum penetration after prior ex vivo, enzymatic, macrophage, and murine lung-infection studies grounded in CF sputum and iron-limited conditions.
Study Design and Methods
| Aspect | Details |
|---|---|
| Design | Translational program combining ex vivo CF sputum assays, mechanistic enzymology, resistance and synergy testing, murine P. aeruginosa lung infection, and an open-label phase 1b nonrandomized human trial in CF adults with chronic P. aeruginosa airway infection. |
| Metal measurement | Gallium delivered as Ga(NO₃)₃; dose expressed as mg/m²/day intravenously. In vitro and ex vivo work used Ga(NO₃)₃ in micromolar concentrations; Fe availability manipulated with FeCl₃ (Fe³⁺, μM). Gallium levels in human plasma and sputum were quantified to generate area-under-the-curve and half-life estimates; units reported as μg/ml. |
| Microbial characterization | Primary organism P. aeruginosa (reference strain PAO1 and derivatives, including pyoverdine mutants and ΔhitAB). Growth in CF sputum supernatant and defined media (BM2, 10% TSB) was monitored. A pvdA–gfp reporter and pyoverdine quantification assessed Fe-starvation responses. Bacterial counts were determined in CF sputum, mouse bronchoalveolar lavage and blood, and oxidant- and drug-exposure assays. |
| Endpoints & sample size | Preclinical endpoints: growth inhibition in CF sputum, Fe-starvation gene induction, activity of Fe-dependent enzymes (ribonucleotide reductase, aconitase, catalase, Fe-SOD), oxidant killing, spontaneous and selected resistance frequency, drug interactions, macrophage viability and killing, and mouse survival/CFU. Human trial (n=20): primary endpoints safety, tolerability, pharmacokinetics; exploratory endpoints change in FEV₁ and FVC (L) at days 7, 14, 28 and sputum P. aeruginosa (million CFU/g). Follow-up extended to 28 days post-infusion. |
Major Findings
The work tightly links disruption of bacterial iron metabolism by Ga³⁺ to both altered P. aeruginosa physiology in iron-limited CF airway conditions and measurable improvements in lung function in CF adults.
In CF sputum supernatant, iron was growth limiting for P. aeruginosa, as low micromolar FeCl₃ increased growth rate and yield while inducing iron-repressed changes in pyoverdine and pvdA expression. Gallium at 4–6 μM completely inhibited P. aeruginosa growth in CF sputum, even when FeCl₃ was added at growth-stimulating concentrations. Mechanistically, Ga³⁺ partially inhibited ribonucleotide reductase activity (~40% inhibition at 20 μM) and markedly reduced catalase activity (≈70% inhibition at 60 μM) without affecting aconitase or Fe-SOD, resulting in increased susceptibility to H₂O₂ and tert-butyl hydroperoxide but not superoxide-generating agents. In mice with acute intratracheal P. aeruginosa infection, a single intraperitoneal dose of gallium nitrate improved survival and reduced lung and blood CFU; intranasal Fe³⁺ mitigated this effect, directly implicating competition with iron. In the CF phase 1b trial, continuous IV gallium achieved sustained plasma (T½ >100 h) and sputum (T½ >220 h) levels, with sputum concentrations peaking after infusion. Across 20 participants, mean FEV₁ rose by 0.13 L at day 14 and 0.10 L at day 28, and FVC increased by 0.13 and 0.16 L at these time points, all with p-values ≤0.004. Sputum P. aeruginosa counts trended downward but did not change significantly.
| Findings | Details |
|---|---|
| CF sputum iron limitation | FeCl₃ addition (sub-10 μM) increased P. aeruginosa growth and suppressed pvdA–gfp and pyoverdine, confirming iron-limited conditions in expectorated CF sputum. |
| Gallium activity in CF sputum | Ga³⁺ (4–5 μM) fully inhibited P. aeruginosa growth in CF sputum; higher concentrations (4–6 μM) remained inhibitory despite FeCl₃ supplementation. |
| Enzymatic and oxidative effects | Ga³⁺ inhibited ribonucleotide reductase and catalase but not aconitase or Fe-SOD, increasing sensitivity to peroxides but not superoxide-generating agents. |
| Resistance and synergy | Spontaneous Ga³⁺ resistance frequency (~1.1 × 10⁻⁷) was similar to colistin, lower than tobramycin, and increased only modestly with passaging; synergy with colistin and piperacillin/tazobactam and antagonism with tobramycin were demonstrated in multiple assays. |
| Clinical and PK outcomes | In 20 CF adults, 5 days of IV gallium nitrate yielded no serious toxicity, sustained plasma/sputum Ga³⁺, significant FEV₁ and FVC improvements through day 28, and non-significant reductions in sputum P. aeruginosa CFU/g. |
Mechanistic Interpretation & Microbial Metallomics
These findings suggest that Ga³⁺ acts as a non-reducible Fe³⁺ mimetic that infiltrates P. aeruginosa iron circuits in CF airways, selectively crippling Fe-dependent processes essential for DNA synthesis and oxidative stress defense while exploiting the intrinsic iron limitation of CF sputum.
| Concept | Implication |
|---|---|
| Ga³⁺–Fe³⁺ ionic mimicry | Bacterial uptake systems import Ga³⁺, but Ga³⁺ cannot undergo Fe²⁺/Fe³⁺ redox cycling, producing dysfunctional Fe-binding enzymes and metabolic “false metal” poisoning. |
| Iron-limited CF airway milieu | Endogenous Fe scarcity in CF sputum enhances Ga³⁺ uptake and activity; added Fe³⁺ reverses Fe-starvation signatures and partially blunts gallium’s effects, underscoring competition at the metallomic level. |
| Selective inhibition of ribonucleotide reductase and catalase | Partial inhibition of DNA synthesis and strong loss of peroxide defense collectively impair growth and survival, especially under host oxidative stress. |
| Unaffected aconitase and Fe-SOD | Specific Fe enzyme targets are differentially susceptible to Ga³⁺, indicating that gallium reshapes rather than globally collapses the Fe-dependent proteome, with redox chemistry likely determining vulnerability. |
| Low-frequency, hitAB-centered resistance | Resistance emerges predominantly via interference with Fe³⁺ (and Ga³⁺) import, with limited additional mutational routes, suggesting a constrained evolutionary path to high-level Ga³⁺ resistance. |
| Synergy with selected antibiotics | Synergism with colistin and piperacillin/tazobactam indicates that perturbing iron metabolism can potentiate membrane-active and cell-wall–targeting drugs, providing a rational metallomic combination strategy. |
Limitations
The antimicrobial studies focused on P. aeruginosa PAO1 and derivatives under specific media conditions, which may not capture strain-to-strain heterogeneity. Resistance and synergy assays, though employing multiple methods, may not fully reflect in vivo dynamics. The human trial was small, open-label, and uncontrolled, with participants having relatively preserved lung function and being studied during clinical stability; microbiologic endpoints were underpowered, and long-term or repeated dosing effects remain unknown.
Future perspectives
Next steps logically include a randomized, placebo-controlled trial of IV gallium in CF patients, ideally enriched for exacerbation episodes and more advanced lung disease, to clarify clinical benefit and microbiologic impact. Inhaled or oral gallium formulations could be explored to optimize airway targeting and chronic dosing while monitoring metallomic competition with Fe²⁺/Fe³⁺ in vivo. Further work dissecting Ga³⁺ binding to specific P. aeruginosa Fe proteins, mapping transcriptomic and metabolomic remodeling in CF sputum, and systematically testing combinations with colistin and piperacillin/tazobactam in patients will refine gallium’s role as a metallomic adjuvant therapy.
Key takeaways for Researchers and Clinicians
This study integrates ex vivo CF sputum work, mechanistic microbiology, murine lung infection, and a phase 1b CF trial to evaluate Ga³⁺ as an iron-mimicking antimicrobial targeting chronic P. aeruginosa infection. Gallium nitrate, delivered intravenously at 100–200 mg/m²/day over 5 days, achieved sustained plasma and sputum levels and was well tolerated. The principal metal of interest is Ga³⁺, acting against Fe³⁺/Fe²⁺ metabolism; low micromolar Ga³⁺ suppressed P. aeruginosa growth in iron-limited CF sputum, inhibited ribonucleotide reductase and catalase, and sensitized bacteria to peroxides. Clinically, mean FEV₁ gains of 0.13 L at day 14 and 0.10 L at day 28, with corresponding FVC improvements and p-values around 0.004, indicate a reproducible, though modest, physiological benefit, while sputum P. aeruginosa CFU/g showed non-significant downward trends.
Methodologically, the study highlights the value of using the native matrix (CF sputum) to define iron limitation and Ga³⁺ potency, pairing enzyme-level assays with oxidant and resistance phenotyping, and cross-walking these to murine and human outcomes. For clinicians, the immediate message is that targeting bacterial iron metabolism with a systemically administered Ga³⁺ salt can be done safely in CF adults and may improve lung function even without large, quantifiable reductions in sputum P. aeruginosa. For microbial metallomics, this work offers a translational proof-of-concept that “false-metal” occupation of Fe-binding sites is a viable therapeutic axis that can intersect meaningfully with conventional antibiotics and host oxidative defenses.
Citation
Goss CH, Kaneko Y, Khuu L, Anderson GD, Ravishankar S, Aitken ML, Lechtzin N, Zhou G, Czyz D, McLean K, et al. Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Sci Transl Med. 2018 Sep 26;10(460). doi:10.1126/scitranslmed.aat7520